Armata Pharmaceuticals (TG1N) Price & Analysis

1 Followers

TG1N Stock Chart & Stats

€4.72

€0.00(0.00%)

At close: Jul 24 4:00 PM EDT

€4.72

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€2.28 - €12.70

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€186.65M

Enterprise Value€692.03

Total Cash (Recent Filing)€23.95M

Total Debt (Recent Filing)€313.95M

Price to Earnings (P/E)―

Beta1.52

Next Earnings

Nov 18, 2026

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.30

Shares Outstanding37,181,980

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-1.04

Price to Sales (P/S)46.41

P/FCF Ratio-8.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€15.04

Price Target Upside218.69% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-2.26

Revenue Forecast (FY)€2.59M

Bulls Say, Bears Say

Bulls Say

Phase 3 ReadinessAP-SA02’s submitted Phase 3 protocol, completed engineering runs, and planned cGMP trial-material production create a clearer path toward pivotal testing. This progress reduces development execution uncertainty and may strengthen the lead program’s prospects if subsequent clinical results remain favorable.

Regulatory PathwayFDA agreement on the pediatric study plan establishes a defined framework for expanding AP-SA02 beyond adults after Phase 3 data. A clearer regulatory route can support future registration planning and broaden the candidate’s potential addressable patient population.

Non-dilutive FundingThe additional DoD funding provides non-dilutive capital for AP-SA02’s Phase 3 preparation, helping finance development without immediately relying solely on equity issuance. Continued federal support also reinforces the strategic relevance of Armata’s phage-therapy program.

Bears Say

Negative Equity And LeverageNegative stockholders’ equity and meaningful debt leave Armata with limited balance-sheet flexibility relative to its operating losses. This strained capital structure can increase financing risk, constrain investment choices, and make continued development more dependent on favorable capital access.

Persistent Cash BurnOngoing operating and free-cash-flow deficits show that Armata is not yet funding operations internally. Continued cash consumption requires external capital to sustain research and clinical programs, creating recurring financing needs that could dilute shareholders or restrict development pace.

Limited Earnings PowerArmata’s small revenue base remains far below the cost structure required to produce positive operating results. Persistent deep losses indicate that commercial earnings power is still distant, leaving performance dependent on clinical progress and future funding rather than established product profitability.

Armata Pharmaceuticals News

Armata Pharmaceuticals announces new published paper on Ar-KM

Armata Pharmaceuticals (ARMP) announced a paper in the Journal of Molecular Biology, a peer-reviewed journal. The publication, titled...

6d ago

ARMP

Analyst Maintains Buy on Armata as AP-SA02 Nears Phase 3, Backed by Regulatory Tailwinds and $20 DCF-Based Price Target

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on ARMP stock, giving a Buy rating on August...

11d ago

ARMP

Armata: Buy Rating Reiterated as AP-SA02 Advances Toward 2H26 Phase 3 Start; $15 Price Target Maintained

Armata Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

27d ago

ARMP

Armata Pharmaceuticals Promotes David House to CFO

An announcement from Armata Pharmaceuticals ( ($ARMP) ) is now available. On July 17, 2026, Armata Pharmaceuticals’ board...

2M ago

ARMP

Armata Advances AP-SA02 Toward Phase 3 Trial Launch

An update from Armata Pharmaceuticals ( ($ARMP) ) is now available. On July 20, 2026, Armata Pharmaceuticals reported...

2M ago

ARMP

Armata provides update on AP-SA02 studies

Armata Pharmaceuticals (ARMP) announced significant clinical, regulatory, manufacturing and operational progress supporting advancement of AP-SA02, the Company’s intravenously...

2M ago

ARMP

Armata promotes David House to CFO

Armata announced the promotion of David House to CFO. House has served as the Company’s Senior Vice President,...

2M ago

ARMP

FDA Pediatric Plan Milestone and Phase 3 Design Support Unchanged $15 Price Target and Buy Rating on Armata (ARMP)

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Armata Pharmaceuticals, retaining the price target of...

2M ago

ARMP

Armata Advances AP-SA02 Pediatric Plan With FDA Agreement

Armata Pharmaceuticals ( ($ARMP) ) has shared an announcement. On July 13, 2026, Armata Pharmaceuticals announced that the...

2M ago

ARMP

Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02

Armata Pharmaceuticals (ARMP) announced that it has received agreement from the U.S. FDA on an Agreed Initial Pediatric...

2M ago

ARMP

Armata Pharmaceuticals granted $2.5M additional non-dilutive award funding

Armata Pharmaceuticals (ARMP) has received an additional $2.5M of non-dilutive funding pursuant to a previously announced Department of...

3M ago

ARMP

Armata gains new DoD funding for AP-SA02 advancement

Armata Pharmaceuticals ( ($ARMP) ) has provided an update. On June 23, 2026, Armata Pharmaceuticals announced it received...

3M ago

ARMP

Armata Shareholders Approve Directors, Executive Pay and Auditor

Armata Pharmaceuticals ( ($ARMP) ) has provided an announcement. At its June 11, 2026 annual shareholder meeting, Armata...

3M ago

ARMP

Analyst Reiterates Buy on Armata, Maintaining $20 Price Target Ahead of Pivotal Phase 3 AP-SA02 Trial

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on ARMP stock, giving a Buy rating on May...

3M ago

ARMP

TG1N FAQ

What was Armata Pharmaceuticals Inc’s price range in the past 12 months?

Armata Pharmaceuticals Inc lowest stock price was €2.28 and its highest was €12.70 in the past 12 months.

What is Armata Pharmaceuticals Inc’s market cap?

Armata Pharmaceuticals Inc’s market cap is €186.65M.

When is Armata Pharmaceuticals Inc’s upcoming earnings report date?

Armata Pharmaceuticals Inc’s upcoming earnings report date is Nov 18, 2026 which is in 70 days.

How were Armata Pharmaceuticals Inc’s earnings last quarter?

Armata Pharmaceuticals Inc released its earnings results on Aug 12, 2026. The company reported -€0.232 earnings per share for the quarter, beating the consensus estimate of -€0.382 by €0.15.

Is Armata Pharmaceuticals Inc overvalued?

According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Armata Pharmaceuticals Inc pay dividends?

Armata Pharmaceuticals Inc does not currently pay dividends.

What is Armata Pharmaceuticals Inc’s EPS estimate?

Armata Pharmaceuticals Inc’s EPS estimate is -0.48.

How many shares outstanding does Armata Pharmaceuticals Inc have?

Armata Pharmaceuticals Inc has 37,181,980 shares outstanding.

What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?

Armata Pharmaceuticals Inc reported an EPS of -€0.232 in its last earnings report, beating expectations of -€0.382. Following the earnings report the stock price went up 1.676%.

Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in DE:TG1N

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Armata Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

11.34%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Armata Pharmaceuticals (TG1N) Earnings & Revenues

Historic Earnings Reports

TG1N Stock 12 Month Forecast

Average Price Target

€15.04

▲(218.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","18":"€18","5.25":"€5.25","9.5":"€9.5","13.75":"€13.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.191213599999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€17.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.0423119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€15.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.8934102,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.89</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.25,9.5,13.75,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.660862584615384,6.6217251692307695,7.582587753846154,8.543450338461538,9.504312923076922,10.465175507692308,11.426038092307692,12.386900676923077,13.34776326153846,14.308625846153845,15.26948843076923,16.230351015384613,{"y":17.191213599999998,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.495562453846154,6.291124907692308,7.086687361538461,7.882249815384615,8.677812269230769,9.473374723076923,10.268937176923076,11.06449963076923,11.860062084615384,12.655624538461538,13.45118699230769,14.246749446153846,{"y":15.0423119,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.330262323076923,5.960524646153846,6.590786969230769,7.221049292307692,7.851311615384615,8.481573938461537,9.11183626153846,9.742098584615384,10.372360907692308,11.002623230769231,11.632885553846153,12.263147876923075,{"y":12.8934102,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >